Acarix AB (publ) (ACIXF) fair value: what the stock is really worth
We calculate from audited financials what Acarix AB (publ) is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Sep 13, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Acarix AB (publ) for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
46‑month range $0.0090 – $0.0700 · fair‑value band $0.0199 – $0.0239 · the $0.0230 price screens above the $0.0219 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Follow Acarix AB (publ) in your weekly email
Every Wednesday you see whether Acarix AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care.
Show more
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.
Stock analysis
Acarix AB (publ) (ACIXF) currently trades at $0.0230, while our model-based Fair Value estimate is $0.0219, implying the stock looks roughly 5.0% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.0199 (bear) to $0.0239 (bull), the price of $0.0230 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Acarix AB (publ) reported revenue of 7.4M SEK in FY2025 versus 3.8M SEK in FY2021, a compound +18.3%/yr. Reported net income was −48.1M SEK in FY2025.
Key figures
Market cap $34.4M · P/S ratio 4.98 · Return on equity −88.3% · Return on assets (EBIT) −91.7% · Revenue (TTM) 6.9M SEK · Revenue growth (YoY) +40.2% · Free cash flow −38.0M SEK · Net cash 30.6M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −5%, ACIXF screens richer than that median.
Fair Value models
Bear $0.0199Fair Value $0.0219Bull $0.0239
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+18.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+76.6%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,909.3% (2020) → −652.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score34 · Bottom 25%
Fair Value upside−5% · Above median
Profitability
Return on assets−49% · Bottom 25%
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth40% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Acarix AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/ACIXF
Frequently asked questions
Is Acarix AB (publ) (ACIXF) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.0219 versus a price of $0.0230, about −5% upside (fairly valued).
What is the fair value of ACIXF?
Our model-based fair value for Acarix AB (publ) is $0.0219 (as of Sep 13, 2026), built from audited fundamentals. The current price: $0.0230.
What is the quality score of ACIXF?
Acarix AB (publ) has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Acarix AB (publ) (ACIXF)?
Our model-based price target is the fair value of $0.0219 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario $0.0199, optimistic scenario $0.0239. It is a calculation from audited fundamentals, not an analyst target.
What is the Acarix AB (publ) stock forecast for 2026?
Our models put fair value at $0.0219, about −5% upside versus a price of $0.0230 (fairly valued). Cautious scenario $0.0199, optimistic scenario $0.0239. The calculation is refreshed regularly with new filings.
What is the revenue of Acarix AB (publ) (ACIXF)?
Acarix AB (publ) reported trailing-twelve-month revenue of about 6.9M SEK (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Acarix AB (publ) (ACIXF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Acarix AB (publ) it is $0.0219 per share (as of Sep 13, 2026), against a price of $0.0230. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Acarix AB (publ) stock overvalued or undervalued in 2026?
As of Sep 13, 2026, ACIXF trades above its calculated fair value: price $0.0230, fair value $0.0219, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACIXF?
No. The price is what the market pays today ($0.0230); the fair value is what the company's own numbers justify ($0.0219). For Acarix AB (publ) the two are $0.0011 per share apart. That gap is exactly why we show both numbers side by side.
How much is Acarix AB (publ) worth?
The market values Acarix AB (publ) at about $34.4M (market capitalisation, as of Sep 13, 2026). Per share that is $0.0230; our models calculate a fair value of $0.0219 per share.
What do the bullish and bearish scenarios say about ACIXF?
Our models span a range for Acarix AB (publ): cautious scenario $0.0199, base $0.0219, optimistic $0.0239 per share (as of Sep 13, 2026, price $0.0230). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Acarix AB (publ) (ACIXF)?
Balance-sheet figures for Acarix AB (publ) (as of Sep 13, 2026): return on equity −88.3%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is ACIXF from its 52-week high?
Acarix AB (publ) trades at $0.0230, about 45% below its 52-week high of $0.0422 and 16% above the low of $0.0199 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0219 is for.
Which stocks are comparable to Acarix AB (publ)?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Acarix AB (publ) stock attractive at the current price?
The data as of Sep 13, 2026: price $0.0230, calculated fair value $0.0219 (−5%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACIXF calculated?
We run Acarix AB (publ) through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0219, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Acarix AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Acarix AB (publ) (ACIXF)?
The closing price on Sep 22, 2026 was $0.0230. Our model-based fair value is $0.0219, about −5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Acarix AB (publ) right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Acarix AB (publ)
How large is the market capitalisation of Acarix AB (publ) (ACIXF)?
The market capitalisation of Acarix AB (publ) is $34.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Acarix AB (publ) (ACIXF)?
The price-to-sales ratio of Acarix AB (publ) is 4.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Acarix AB (publ) (ACIXF)?
The return on equity (ROE) of Acarix AB (publ) is −88.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Acarix AB (publ) (ACIXF)?
On an EBIT basis the return on assets of Acarix AB (publ) is −91.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Acarix AB (publ) (ACIXF)?
Revenue at Acarix AB (publ) is growing +40.2% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Acarix AB (publ) (ACIXF) generate?
The free cash flow of Acarix AB (publ) is −38.0M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Acarix AB (publ) (ACIXF) hold?
Acarix AB (publ) holds more cash than debt, 30.6M SEK net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Acarix AB (publ) in the live analysis
One click puts Acarix AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 13, 2026